Literature DB >> 500504

Growth inhibition of virus transformed cells in vitro and antitumor activity in vivo of geldanamycin and its derivatives.

K Sasaki, H Yasuda, K Onodera.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 500504     DOI： 10.7164/antibiotics.32.849

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN： 0021-8820            Impact factor:   2.649


× No keyword cloud information.
  11 in total

Review 1.  Geldanamycin: the prototype of a class of antitumor drugs targeting the heat shock protein 90 family of molecular chaperones.

Authors:  H J Ochel; K Eichhorn; G Gademann
Journal:  Cell Stress Chaperones       Date:  2001-04       Impact factor: 3.667

Review 2.  Chemical approaches to controlling intracellular protein degradation.

Authors:  John S Schneekloth; Craig M Crews
Journal:  Chembiochem       Date:  2005-01       Impact factor: 3.164

3.  Genetic and biochemical analysis of p23 and ansamycin antibiotics in the function of Hsp90-dependent signaling proteins.

Authors:  S P Bohen
Journal:  Mol Cell Biol       Date:  1998-06       Impact factor: 4.272

4.  Geldanamycin disrupts platelet-membrane structure, leading to membrane permeabilization and inhibition of platelet aggregation.

Authors:  S Suttitanamongkol; A R Gear; R Polanowska-Grabowska
Journal:  Biochem J       Date:  2000-01-15       Impact factor: 3.857

5.  Insights into the biosynthesis of the benzoquinone ansamycins geldanamycin and herbimycin, obtained by gene sequencing and disruption.

Authors:  Andreas Rascher; Zhihao Hu; Greg O Buchanan; Ralph Reid; C Richard Hutchinson
Journal:  Appl Environ Microbiol       Date:  2005-08       Impact factor: 4.792

6.  Synthesis of reblastatin, autolytimycin, and non-benzoquinone analogues: potent inhibitors of heat shock protein 90.

Authors:  Iwona E Wrona; Alexander Gozman; Tony Taldone; Gabriela Chiosis; James S Panek
Journal:  J Org Chem       Date:  2010-05-07       Impact factor: 4.354

7.  Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies.

Authors:  Erin Schenk; Andrea E Wahner Hendrickson; Donald Northfelt; David O Toft; Matthew M Ames; Michael Menefee; Daniel Satele; Rui Qin; Charles Erlichman
Journal:  Invest New Drugs       Date:  2013-03-31       Impact factor: 3.850

8.  Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent.

Authors:  J G Supko; R L Hickman; M R Grever; L Malspeis
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 9.  Spotlight on the microbes that produce heat shock protein 90-targeting antibiotics.

Authors:  Peter W Piper; Stefan H Millson
Journal:  Open Biol       Date:  2012-12-12       Impact factor: 6.411

10.  Synthesis and antiviral activity of some novel indole-2-carboxylate derivatives.

Authors:  Situ Xue; Linlin Ma; Rongmei Gao; Yuhuan Li; Zhuorong Li
Journal:  Acta Pharm Sin B       Date:  2014-07-16       Impact factor: 11.413
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.